Filing Flows › Amgen (AMGN) › R&D spending
Amgen (AMGN) R&D spending by quarter
Amgen's R&D spending was $2.1B in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 6 quarters it ranged from $1.5B (Q1 2025) to $2.1B (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.1B | +13% | +11% |
| Q2 2026 | $1.9B | -13% | +7% |
| Q4 2025 | $2.1B | +13% | — |
| Q3 2025 | $1.9B | +9% | — |
| Q2 2025 | $1.7B | +17% | — |
| Q1 2025 | $1.5B | — | — |
Q3 2026 at a glance
Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%, net earnings $3.9B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Questions
What is Amgen's R&D spending?
Amgen's R&D spending was $2.1B in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has Amgen's R&D spending changed?
Over the last 6 quarters it ranged from $1.5B (Q1 2025) to $2.1B (Q4 2025).